Around 6 million people are suffering from Parkinson disease worldwide. ; In the US, cost is about $23 billion per
year. There is no cure, actual treatments are helping relieve the symptoms and maintain in certain level the patient
quality of life : L-DOPA/ DOPA agonists ; COMT & MAO inhibitors have lack of efficiency and significant side effects.
LRRK2 phosphorylation has an important effect in PD pathogenesis. We propose a new therapeutic
peptides which targets PP1/ LRRK2 interaction, allowing the manipulation of PP1 effect on LRRK2.
Competitive advantages :
Keywords : Parkinson’s Disease - Interfering peptides - PP1 - LRRK2
Cell penetrating and interfering peptides